Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

340B Lobby Group Seeks Bill Changing Hospital Eligibility For Discount Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

A group supported by drug manufacturers and pharmacy benefit managers – the Alliance for Integrity and Reform of 340B – is pushing Congress to alter how hospitals qualify for discounted drugs under the 340B program.

You may also be interested in...



340B Needs Legislative Fix For Overspending On Medicare Patients, GAO Says

Drug discount program creates financial incentive for participating hospitals to prescribe more drugs or more expensive drugs reimbursed by Medicare Part B, resulting in 'substantially higher' spending, a GAO report says.

340B Purchases To Hit 8% Of Outpatient Brand Drug Sales In 2019 – White Paper

Berkeley Research Group finds fault with the oft-cited idea that 340B accounts for only 2% of total drug sales. Meanwhile, 340B hospitals issue their own data showing they serve lower-income populations than other hospitals.

Goodbye ‘340B,’ Hello ‘Outpatient Drug Discount Program’ In House Reform Bill

House Commerce Committee members are drafting legislation to make numerous significant changes to the 340B drug discount program, including the definition of eligible patients, new reporting and auditing requirements for providers and drug manufacturers, rules for contract pharmacies – and a new user-fee program for participating health care providers.

Related Content

Topics

UsernamePublicRestriction

Register

PS076996

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel